331 related articles for article (PubMed ID: 23454865)
21. From reactivation of latent HIV-1 to elimination of the latent reservoir: the presence of multiple barriers to viral eradication.
Shan L; Siliciano RF
Bioessays; 2013 Jun; 35(6):544-52. PubMed ID: 23613347
[TBL] [Abstract][Full Text] [Related]
22. Reservoirs of HIV-1 in vivo: implications for antiretroviral therapy.
Saksena NK; Potter SJ
AIDS Rev; 2003; 5(1):3-18. PubMed ID: 12875103
[TBL] [Abstract][Full Text] [Related]
23. HIV-1 can be recovered from a variety of cells including peripheral blood monocytes of patients receiving highly active antiretroviral therapy: a further obstacle to eradication.
Crowe SM; Sonza S
J Leukoc Biol; 2000 Sep; 68(3):345-50. PubMed ID: 10985250
[TBL] [Abstract][Full Text] [Related]
24. Reservoirs, sanctuaries, and residual disease: the hiding spots of HIV-1.
Pomerantz RJ
HIV Clin Trials; 2003; 4(2):137-43. PubMed ID: 12671782
[TBL] [Abstract][Full Text] [Related]
25. Th1/17 Polarization of CD4 T Cells Supports HIV-1 Persistence during Antiretroviral Therapy.
Sun H; Kim D; Li X; Kiselinova M; Ouyang Z; Vandekerckhove L; Shang H; Rosenberg ES; Yu XG; Lichterfeld M
J Virol; 2015 Nov; 89(22):11284-93. PubMed ID: 26339043
[TBL] [Abstract][Full Text] [Related]
26. Nanoparticle-Based Immunoengineered Approaches for Combating HIV.
Bowen A; Sweeney EE; Fernandes R
Front Immunol; 2020; 11():789. PubMed ID: 32425949
[TBL] [Abstract][Full Text] [Related]
27. Pharmacokinetics of antiretroviral drugs in anatomical sanctuary sites: the male and female genital tract.
Else LJ; Taylor S; Back DJ; Khoo SH
Antivir Ther; 2011; 16(8):1149-67. PubMed ID: 22155899
[TBL] [Abstract][Full Text] [Related]
28. Finding a cure for HIV: will it ever be achievable?
Lewin SR; Evans VA; Elliott JH; Spire B; Chomont N
J Int AIDS Soc; 2011 Jan; 14():4. PubMed ID: 21255462
[TBL] [Abstract][Full Text] [Related]
29. Cellular and anatomical reservoirs of HIV-1 in patients receiving potent antiretroviral combination therapy.
Schrager LK; D'Souza MP
JAMA; 1998 Jul; 280(1):67-71. PubMed ID: 9660366
[TBL] [Abstract][Full Text] [Related]
30. Strategies for overcoming resistance in HIV-1 infected patients receiving HAART.
Clotet B
AIDS Rev; 2004; 6(3):123-30. PubMed ID: 15595429
[TBL] [Abstract][Full Text] [Related]
31. New Insights into HIV-1 Persistence in Sanctuary Sites During Antiretroviral Therapy.
Poveda E; Tabernilla A
AIDS Rev; 2016; 18(1):55. PubMed ID: 27028272
[TBL] [Abstract][Full Text] [Related]
32. Improving bioavailability and biodistribution of anti-HIV chemotherapy.
Giacalone G; Hillaireau H; Fattal E
Eur J Pharm Sci; 2015 Jul; 75():40-53. PubMed ID: 25937367
[TBL] [Abstract][Full Text] [Related]
33. Differences in HIV Markers between Infected Individuals Treated with Different ART Regimens: Implications for the Persistence of Viral Reservoirs.
Darcis G; Berkhout B; Pasternak AO
Viruses; 2020 Apr; 12(5):. PubMed ID: 32349381
[TBL] [Abstract][Full Text] [Related]
34. Antiretroviral Therapy Concentrations Differ in Gut vs. Lymph Node Tissues and Are Associated With HIV Viral Transcription by a Novel RT-ddPCR Assay.
Lee SA; Telwatte S; Hatano H; Kashuba ADM; Cottrell ML; Hoh R; Liegler TJ; Stephenson S; Somsouk M; Hunt PW; Deeks SG; Yukl S; Savic RM
J Acquir Immune Defic Syndr; 2020 Apr; 83(5):530-537. PubMed ID: 32168200
[TBL] [Abstract][Full Text] [Related]
35. Preclinical pharmacokinetics and tissue distribution of long-acting nanoformulated antiretroviral therapy.
Gautam N; Roy U; Balkundi S; Puligujja P; Guo D; Smith N; Liu XM; Lamberty B; Morsey B; Fox HS; McMillan J; Gendelman HE; Alnouti Y
Antimicrob Agents Chemother; 2013 Jul; 57(7):3110-20. PubMed ID: 23612193
[TBL] [Abstract][Full Text] [Related]
36. Mechanisms underlying of antiretroviral drugs in different cellular reservoirs with a focus on macrophages.
Aquaro S; Borrajo A; Pellegrino M; Svicher V
Virulence; 2020 Dec; 11(1):400-413. PubMed ID: 32375558
[TBL] [Abstract][Full Text] [Related]
37. The crosstalk between antiretrovirals pharmacology and HIV drug resistance.
Giacomelli A; Pezzati L; Rusconi S
Expert Rev Clin Pharmacol; 2020 Jul; 13(7):739-760. PubMed ID: 32538221
[TBL] [Abstract][Full Text] [Related]
38. Barriers to HIV Cure.
Stein J; Storcksdieck Genannt Bonsmann M; Streeck H
HLA; 2016 Oct; 88(4):155-63. PubMed ID: 27620852
[TBL] [Abstract][Full Text] [Related]
39. Spatial modeling of HIV cryptic viremia and 2-LTR formation during raltegravir intensification.
Cardozo EF; Luo R; Piovoso MJ; Zurakowski R
J Theor Biol; 2014 Mar; 345():61-9. PubMed ID: 24378646
[TBL] [Abstract][Full Text] [Related]
40. HIV persistence in lymph nodes.
Banga R; Munoz O; Perreau M
Curr Opin HIV AIDS; 2021 Jul; 16(4):209-214. PubMed ID: 34059608
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
